Clark Estates Inc. NY lifted its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 6.3% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 850,000 shares of the medical equipment provider's stock after buying an additional 50,000 shares during the quarter. Smith & Nephew SNATS makes up 5.1% of Clark Estates Inc. NY's holdings, making the stock its 3rd largest holding. Clark Estates Inc. NY owned 0.19% of Smith & Nephew SNATS worth $24,114,000 at the end of the most recent quarter.
A number of other large investors also recently modified their holdings of SNN. Hexagon Capital Partners LLC lifted its stake in shares of Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 406 shares in the last quarter. Richards Merrill & Peterson Inc. lifted its stake in Smith & Nephew SNATS by 500.0% in the 1st quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock worth $34,000 after purchasing an additional 1,000 shares in the last quarter. National Bank of Canada FI lifted its stake in Smith & Nephew SNATS by 36.5% in the 4th quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after purchasing an additional 446 shares in the last quarter. Bessemer Group Inc. lifted its stake in Smith & Nephew SNATS by 3,471.4% in the 1st quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 1,701 shares in the last quarter. Finally, Hara Capital LLC lifted its stake in Smith & Nephew SNATS by 391.4% in the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 1,957 shares in the last quarter. Hedge funds and other institutional investors own 25.64% of the company's stock.
Smith & Nephew SNATS Price Performance
Shares of Smith & Nephew SNATS stock traded up $0.31 during trading hours on Friday, reaching $30.87. The company's stock had a trading volume of 951,119 shares, compared to its average volume of 870,857. The firm has a 50 day moving average price of $29.93 and a 200-day moving average price of $28.06. Smith & Nephew SNATS, Inc. has a one year low of $23.69 and a one year high of $31.84. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.89 and a quick ratio of 1.33. The stock has a market cap of $13.52 billion, a P/E ratio of 14.29, a P/E/G ratio of 0.95 and a beta of 0.69.
Analysts Set New Price Targets
Several brokerages have commented on SNN. HSBC cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Canaccord Genuity Group boosted their price target on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Finally, Hsbc Global Res cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Six investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Smith & Nephew SNATS presently has a consensus rating of "Hold" and an average price target of $28.00.
Read Our Latest Analysis on SNN
Smith & Nephew SNATS Company Profile
(
Free Report)
Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.
Read More

Before you consider Smith & Nephew SNATS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.
While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.